Last update 04 Oct 2025

HZ-Q1070

Overview

Basic Info

Drug Type
Proteolysis-targeting chimeras (PROTAC)
Synonyms
HZ-Q1070
Target
BTK
Action
degraders
Mechanism
BTK degraders(Tyrosine-protein kinase BTK degraders)
Therapeutic Areas
NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases
Active Indication
B-Cell Malignant NeoplasmAutoimmune DiseasesHematologic Neoplasms+ [2]
Inactive Indication-
Originator Organization
Hangzhou Hertz Pharmaceutical Co. Ltd.Hangzhou Hertz Pharmaceutical Co. Ltd.
Active Organization
Bohai Rim Advanced Research Institute for Drug DiscoveryHangzhou Hertz Pharmaceutical Co. Ltd.Hangzhou Hertz Pharmaceutical Co. Ltd.Shanghai Institute of Materia Medica Chinese Academy of SciShanghai Institute of Materia Medica Chinese Academy of Sci
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with HZ-Q1070
CTR20240471
/ RecruitingPhase 1
一项评价BTK蛋白降解剂HZ-Q1070治疗复发或难治性B细胞恶性肿瘤的安全性/耐受性和药代动力学/药效动力学的I期临床研究
[Translation] A Phase I clinical study evaluating the safety/tolerability and pharmacokinetics/pharmacodynamics of the BTK protein degrader HZ-Q1070 in the treatment of relapsed or refractory B-cell malignancies
100 Clinical Results associated with HZ-Q1070
Login to view more data
100 Translational Medicine associated with HZ-Q1070
Login to view more data
100 Patents (Medical) associated with HZ-Q1070
Login to view more data
100 Deals associated with HZ-Q1070
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
B-Cell Malignant NeoplasmPhase 1
China
Shanghai Institute of Materia Medica Chinese Academy of SciShanghai Institute of Materia Medica Chinese Academy of Sci
25 Mar 2024
B-Cell Malignant NeoplasmPhase 1
China
Hangzhou Hertz Pharmaceutical Co. Ltd.Hangzhou Hertz Pharmaceutical Co. Ltd.
25 Mar 2024
B-Cell Malignant NeoplasmPhase 1
China
Bohai Rim Advanced Research Institute for Drug Discovery
25 Mar 2024
Autoimmune DiseasesPhase 1
China
Hangzhou Hertz Pharmaceutical Co. Ltd.Hangzhou Hertz Pharmaceutical Co. Ltd.
-
Hematologic NeoplasmsPhase 1
China
Hangzhou Hertz Pharmaceutical Co. Ltd.Hangzhou Hertz Pharmaceutical Co. Ltd.
-
B-cell lymphoma recurrentIND Approval
China
Bohai Rim Advanced Research Institute for Drug Discovery
20 Nov 2023
B-cell lymphoma recurrentIND Approval
China
Hangzhou Hertz Pharmaceutical Co. Ltd.Hangzhou Hertz Pharmaceutical Co. Ltd.
20 Nov 2023
B-cell lymphoma recurrentIND Approval
China
Shanghai Institute of Materia Medica Chinese Academy of SciShanghai Institute of Materia Medica Chinese Academy of Sci
20 Nov 2023
B-cell lymphoma refractoryIND Approval
China
Bohai Rim Advanced Research Institute for Drug Discovery
20 Nov 2023
B-cell lymphoma refractoryIND Approval
China
Hangzhou Hertz Pharmaceutical Co. Ltd.Hangzhou Hertz Pharmaceutical Co. Ltd.
20 Nov 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free